Brief: Kezar Life Sciences And Everest Medicines Enter Into An Agreement To Develop And Commercialize Zetomipzomib For Lupus Nephritis And Other Potential Indications In Greater China, South Korea And Southeast Asia
20/09/2023 23:30
Kezar Life Sciences Inc KZR.O :
* KEZAR LIFE SCIENCES AND EVEREST MEDICINES ENTER INTO AN
AGREEMENT TO DEVELOP AND COMMERCIALIZE ZETOMIPZOMIB FOR LUPUS
NEPHRITIS AND OTHER POTENTIAL INDICATIONS IN GREATER CHINA,
SOUTH KOREA AND SOUTHEAST ASIA
* KEZAR LIFE SCIENCES INC - KEZAR IS ELIGIBLE TO RECEIVE UP
TO
$132.5 MILLION IN TOTAL PAYMENTS, AS WELL AS TIERED ROYALTIES
* KEZAR LIFE SCIENCES INC - EVEREST MEDICINES WILL ALSO PAY
TIERED
ROYALTIES ON NET SALES
Source text for Eikon: ID:nBw1ZQ2la
Further company coverage: KZR.O
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region